IL-17, IL-23, IκBζ, inflammation, autoimmune disease, dermatology

Temisis is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing a strong inflammatory component.
Our main asset in dermatology, TEM1657, is a brand-new small molecule that acts via inhibition of IκBζ and shows major efficacy at a pre-clinical stage to remit psoriasis symptoms both when administered orally or topically.